Browsing Tag
ADA 2025
13 posts
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation
OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.
Cirius Therapeutics shows 0602K and tirzepatide combo preserves muscle and burns fat in obesity and type 2 diabetes
Cirius Therapeutics unveils new ADA 2025 data showing MPC inhibitor 0602K significantly improves muscle and fat metabolism when combined with tirzepatide.
Replacing diet drinks with water more than doubles type 2 diabetes remission in women, ADA 2025 study shows
A new ADA 2025 study shows that women with type 2 diabetes who replaced diet drinks with water saw 90% remission rates and greater weight loss outcomes.
Stem cell-based diabetes therapies at ADA 2025 show promise in eliminating insulin use for type 1 patients
VX-880 and immune-shielded stem cell islets show strong promise in clinical trials at ADA 2025, offering new possibilities in type 1 diabetes treatment.
Semaglutide shows significant vascular benefits in PAD patients with type 2 diabetes, STRIDE trial confirms
Semaglutide improves walking capacity and reduces disease progression in PAD patients with type 2 diabetes, STRIDE trial results reveal at ADA 2025.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
Neodyne Biosciences and Gan & Lee Pharmaceuticals reveal major clinical advances in diabetes care at ADA 2025
Neodyne Biosciences and Gan & Lee Pharmaceuticals presented major ADA 2025 clinical results showing new treatment paths for lipohypertrophy and type 2 diabetes.
Smart insulin system improves glucose control for pregnant women with type 1 diabetes, according to ADA 2025 clinical trial findings
Smart insulin system shows improved glucose control in pregnancy with type 1 diabetes, per ADA 2025 trial; regulatory expansion expected. Read full details.
How are AI models and new clinical treatments reshaping diabetes care after the 2025 ADA conference?
ADA 2025 highlights AI diagnostics and breakthrough injectables in diabetes care, signaling early detection and superior glycemic control in clinical trials.